DOTmed March 7, 2025
Boston Scientific has announced a definitive agreement to acquire SoniVie Ltd., a privately held medical device company specializing in ultrasound-based therapies for hypertension.
The deal, valued at up to $540 million, will add SoniVie’s TIVUS Intravascular Ultrasound System to Boston Scientific’s interventional cardiology portfolio.
The TIVUS system is an investigational device designed for renal artery denervation (RDN), a procedure that targets nerves surrounding the renal arteries to help regulate blood pressure. Unlike traditional radiofrequency-based RDN, the ultrasound-based approach has the potential to penetrate tissue more deeply, which may result in shorter procedures and effective nerve ablation.
“Renal denervation for hypertension is an exciting medical advancement for the millions of patients it may help and is supported by positive results from...
Today's Sponsors
Today's Sponsor